Program seeks to find miRNA biomarkers that can be used as prognostic indicators.

Rosetta Genomics will be working with NYU Medical Center to develop a diagnostic test for melanoma. The partners will focus on identifing miRNAs that can be used as prognostic indicators for the overall survival of melanoma patients and the risk that the disease will metastasize to distant sites.

“We believe that through our work with microRNAs, which have been shown to hold tremendous potential as biomarkers, we will be able to better understand both the origins and the development of the disease,” comments Eva Hernando of the department of pathology at the NYU School of Medicine. “NYU’s extensive experience with melanoma combined with Rosetta Genomics knowledge in microRNAs offers an exciting research opportunity.”

Previous article14 Companies to Vie for $1.65B Market Generated by GSK’s Cardiovascular Drug with Copycat Products
Next articleMethod to Enhance Lethality of Bactericidal Antibiotics against Superbugs Uncovered